ShockWave Medical (NASDAQ:SWAV) had its price target hoisted by equities research analysts at Morgan Stanley from $204.00 to $210.00 in a research note issued to investors on Friday, Benzinga reports. The brokerage currently has an "equal weight" rating on the stock. Morgan Stanley's price target would indicate a potential upside of 22.21% from the stock's current price.
https://www.marketbeat.com/instant-alerts/nasdaq-swav-a-buy-or-sell-right-now-2022-01/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.